News

A new study hopes to gain some clarity on what causes some breast cancer patients to feel "foggy" when receiving chemotherapy.

Recent statistics predict lifetime probabilities.

Karen Chelcun Schreiber was first touched by gastric cancer in 1982, when her mother Elaine died of the disease at age 52. She was impacted again in 2007 when her brother Greg was diagnosed with Stage IV gastric cancer. He was 56.

Big data just got bigger in the realm of cancer survivorship research.

Following treatment with high-dose chemotherapy and stem cell transplant, patients with relapsed and difficult- to-treat Hodgkin lymphoma who received brentuximab vedotin had an unprecedented 50% higher likelihood of continuing to experience progression- free survival (PFS) at 2 years.

Common myths about lung cancer.

The FDA has issued a safety advisory warning healthcare professionals not to use Treanda (bendamustine HCl) Injection with closed system transfer devices (CSTDs), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS).

Tyrosine-kinase inhibitors (TKIs) are a mainstay of therapy for patients with advanced thyroid cancer, more than doubling progression-free survival. Unfortunately, their use is limited not only by gastrointestinal adverse events (AEs), such as diarrhea and anorexia, but also by significant weight loss, which has been reported in 10% to 50% of patients treated with TKI therapies.

According to a recent retrospective cohort analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than do the general population, particularly if they receive adjuvant radiation therapy.

Having a family history of prostate cancer among first-degree relatives may also increase a women's risk of developing breast cancer, according to a new study.

Optimistic messages convey a higher level of compassion.

The FDA has approved nivolumab (Opdivo) for the treatment of patients with advanced squamous non–small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.

The FDA's approval of panobinostat (Farydak) for multiple myeloma, the first histone deacetylase (HDAC) inhibitor to be approved in this space, provides a new option and new hope for patients with this disease, Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation, said.

Results of a new study may help boost lung cancer clinical trial enrollment.

With a career as remarkable and distinguished as Joan Lunden's, it's really no surprise that she took on her latest challenge-a diagnosis of triple-negative breast cancer-with such determination and grace.

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who discussed his position at the 32nd Annual Miami Breast Cancer Conference on Sunday.

Eight signs now identified.

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Pain in patients with breast cancer who have had surgery or who have late-stage disease is common, and managing it effectively can be difficult.

Two new studies highlight the need for cancer survivors and their families to get guidance on healthy lifestyle changes and when the best time might be to integrate them.

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients, according to results of a new study, the first to examine long-term outcomes of patients with low- versus intermediate-risk prostate cancer who have been managed with this conservative approach to care.

Online patient education program provides short videos.

SPOHNC is very pleased to announce that the long-anticipated and updated version of We Have Walked in Your Shoes: A Guide to Living with Oral, Head, and Neck Cancer Second Edition is now available!

Women with HR-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent- tamoxifen compared with standard tamoxifen alone, according to results from the phase III SOFT trial.

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

A study involving more than 1000 patients enrolled in randomized clinical trials has found that patient and physician assessment of treatment toxicities can vary greatly, and they are frequently under-reported by physicians.

A study has found that a large number of women diagnosed with breast cancer know little about the basic characteristics of the cancer:

The Center for Medicare & Medicaid Services (CMS) has announced a new initiative which it hopes will improve the coordination and quality of cancer care for Medicare patients with cancer while also reducing costs.

A new analysis has shown that taking hormone replacement therapy to alleviate symptoms associated with menopause significantly increases the risk of developing the two most common types of ovarian cancer, even if the therapy is only taken for a few years.

Camille Grammer, Real Housewife of Beverly Hills and one-year survivor of endometrial cancer, will lend her voice and celebrity to raising awareness about gynecologic cancers by serving as Chair of the 2015 National Race to End Women's Cancer to be held Sunday, Nov. 8 in Washington, D.C.